Therefore, the overall verdict of this study is that the program for diagnosing a germline mutation in the BRCA1/2 genes and for preventative strategies should be considered cost effective when its impact on family members of patients diagnosed with ovarian cancer is assessed. The gene discussed is BRCA1; the disease is ovarian cancer.